Skip to content
Aarti Drugs logo

Aarti Drugs

AARTIDRUGS NSE
₹447.90 45.65 (11.35%)
Market Cap
₹4,088 Cr
P/E
21.38

Aarti Drugs (AARTIDRUGS) share price was ₹447.90 at the 28 Oct 2026 close; market capitalisation ₹4,088 Cr; P/E (TTM) 21.38; sector Healthcare. The share price fell 6.9% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue rose 19.0% year on year to ₹702.8 Cr and net profit fell 7.2% year on year to ₹50.1 Cr (compared with Jun 2025). Promoters held 54.07% of Aarti Drugs in Sep 2026, down 0.36 percentage points from Jun 2026. Its Tapetide Score is 57/100 (Good) as of 28 Oct 2026.

Close 28 Oct 2026 ₹447.90 −33.20 −6.90% 1Y

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare
Market Cap
₹4,088 Cr
P/E (TTM)
21.38
EBITDA
₹312 Cr
Return on Equity
12.58%
Debt to Equity
0.37
Book Value
₹169.70
EPS (TTM)
₹20.95
52W High
₹534.00
52W Low
₹318.95

Price-based figures as of 28 Oct 2026, 15:59 IST · EPS basis: Consolidated · TTM

Peer Comparison

Healthcare › Pharmaceuticals

Sun Pharma
₹1,757.5034.864,21,683 Cr5.050.91%13.79%17.94%61,848 Cr12,117 Cr
Divis Laboratories
₹9,558.5086.752,53,748 Cr15.140.32%15.32%18.96%11,682 Cr2,925 Cr
Torrent Pharmaceuticals
₹4,557.0071.541,73,334 Cr9.430.82%12.16%9.06%17,058 Cr2,156 Cr
Laurus Labs
₹2,181.90107.801,17,891 Cr22.240.09%16.38%19.67%7,323 Cr1,090 Cr
Zydus Life Science
₹1,175.5026.161,17,257 Cr4.330.09%16.99%19.24%28,515 Cr4,593 Cr
Dr Reddys Laboratories
₹1,335.4034.591,11,463 Cr2.870.61%10.87%13.94%34,247 Cr3,184 Cr
Cipla
₹1,365.6032.721,10,321 Cr3.120.96%11.21%14.88%28,589 Cr3,356 Cr
Aarti Drugs (this company)
₹447.9021.384,088 Cr2.640.50%12.58%12.92%2,681 Cr191 Cr
Median 8 companies₹1,561.5534.731,17,574 Cr4.690.55%13.19%16.41%22,787 Cr3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100. How it works →

As of 2026-10-28
v2.0.0
57 Good
Overall score
Data confidence 100/100

Category scores

Quality Good 64
Returns, margins, earnings quality 22%
Valuation Strong 75
Cheap vs sector & own history 24%
Growth Weak 39
Sales & profit trajectory 9%
Financial Health Weak 40
Solvency, leverage, coverage 9%
Momentum Average 55
Trend strength, vol-adjusted 12%
Ownership Average 54
FII/DII/promoter flows 24%

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Weaknesses

5
  • Promoter holding has decreased over last quarter: -0.36%
  • The company has delivered a poor sales growth of 3.55% over past five years.
  • Company has a low return on equity of 13.3% over last 3 years.
  • Company might be capitalizing the interest cost
  • Dividend payout has been low at 6.72% of profits over last 3 years

Technical Indicators

Oscillators

BearishNeutralBullish

Bullish

Bearish
2
Neutral
4
Bullish
3

Overall

BearishNeutralBullish

Bullish

Bearish
2
Neutral
4
Bullish
13

Moving Averages

BearishNeutralBullish

Bullish

Bearish
0
Neutral
0
Bullish
10
Analyst Rating
Based on 1 analysts
HOLD SHARE100%

0 of 1 analyst rates Buy, 1 Hold, 0 Sell.

Updated 28 Oct 2026

BUY
0
0%
HOLD
1
100%
SELL
0
0%

Growth Rate

Revenue Growth
6.84% higher than 3Y

change over 1 year

Net Income Growth
15.94% higher than 3Y

change over 1 year

Cash Flow Change
3.66%

change over 1 year

EBITDA Margin Change
-3.88%

change over 1 year Operating margin 14% · Jun 2026

Analyst Forecasts

Forecast For
FY27 consensus · EBITDA
₹404 Cr +29.5% vs FY26
Reported High Mean Low

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
661
642
606
620
555
598
557
677
591
653
602
720
703
Expenses
577
565
536
534
490
531
495
583
516
569
547
624
605
Operating Profit
84
76
70
86
65
67
62
93
74
84
55
96
98
OPM %
13%
12%
12%
14%
12%
11%
11%
14%
13%
13%
9%
13%
14%
Other Income
1
1
2
1
1
1
12
2
0
0
1
1
-1
Interest
9
8
8
9
9
9
9
9
9
8
9
8
9
Depreciation
13
13
13
14
13
14
14
15
15
16
18
18
18
PBT
64
56
52
64
44
46
51
71
51
60
29
70
69
Tax %
24%
30%
29%
26%
24%
24%
27%
12%
-6%
25%
-40%
21%
28%
Net Profit
48
40
37
47
33
35
37
63
54
45
41
55
50
EPS (₹)
5.17
4.31
3.99
5.15
3.62
3.84
4.06
6.89
5.91
4.96
4.44
6.05
5.5
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
1,097
1,140
1,195
1,244
1,561
1,806
2,155
2,489
2,716
2,529
2,387
2,565
2,678
Expenses
925
960
1,005
1,042
1,350
1,541
1,714
2,156
2,407
2,208
2,097
2,254
2,344
Operating Profit
172
180
190
202
211
266
440
333
309
321
290
312
333
OPM %
16%
16%
16%
16%
14%
15%
20%
13%
11%
13%
12%
12%
12%
Other Income
1
0
4
1
6
6
5
11
2
4
16
2
1
Interest
42
48
40
38
44
37
26
24
37
38
39
36
34
Depreciation
31
37
38
40
43
49
50
50
50
51
56
67
71
PBT
100
95
116
125
131
185
369
270
224
236
212
211
229
Tax %
23%
28%
29%
34%
32%
24%
24%
24%
26%
27%
21%
8%
—
Net Profit
77
69
82
82
90
141
280
205
166
172
168
195
191
EPS (₹)
7.97
7.09
8.57
8.73
9.52
15.17
30.09
22.14
17.96
18.65
18.42
21.36
20.95
Div. Payout %
41%
24%
3%
3%
3%
3%
8%
5%
6%
5%
5%
9%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
24
24
24
24
24
23
93
93
93
92
91
91
Reserves
284
333
376
432
520
629
820
944
1,100
1,190
1,278
1,458
Borrowings
448
483
480
546
507
389
351
543
609
564
615
577
Other Liabilities
248
261
311
388
405
535
502
629
620
587
591
690
Total Liabilities
1,004
1,102
1,191
1,389
1,455
1,576
1,766
2,208
2,421
2,432
2,575
2,815
Fixed Assets
448
493
581
602
625
644
665
690
676
811
866
1,086
CWIP
16
34
14
28
33
12
19
77
210
261
330
214
Investments
5
5
12
11
12
13
17
19
19
20
22
27
Other Assets
534
570
584
748
785
907
1,064
1,422
1,516
1,340
1,356
1,488
Total Assets
1,004
1,102
1,191
1,389
1,455
1,576
1,766
2,208
2,421
2,432
2,575
2,815
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
105
133
175
70
143
251
155
70
133
359
245
254
Investing
-107
-99
-107
-74
-62
-33
-72
-150
-164
-224
-165
-173
Financing
1
-33
-68
4
-80
-215
-81
92
17
-136
-82
-77
Net Cash Flow
-1
1
0
0
1
2
2
13
-14
-1
-2
3
Free Cash Flow
-2
34
68
-5
80
214
78
-82
-31
133
67
80
CFO/EBITDA
69
85
103
47
82
110
57
46
62
131
103
80
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
105
106
91
110
107
99
94
110
116
102
115
118
Inventory Days
82
86
100
132
86
102
117
115
101
107
114
112
Days Payable
83
90
94
123
85
104
93
103
94
94
100
109
Cash Conversion Cycle
104
103
97
119
109
97
118
123
123
115
129
121
Working Capital Days
14
19
22
33
44
54
77
63
72
74
76
76
ROCE %
—
18%
18%
17%
17%
21%
34%
21%
15%
15%
13%
12%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Aarti Drugs insights

67 extracted metrics + investor summaries across FY06–FY27.

Shareholding Pattern

FIIs2.26%Promot.54.07%Others9.57%DIIs10.24%Public23.86%As ofSep 2026
2.51% of promoter holding pledged as of Sep 2026

Documents

Frequently Asked Questions about Aarti Drugs

What does Aarti Drugs Ltd do?
Established in the year 1984 and a part of $1000 million Aarti Group of Industries, Aarti Drugs Ltd. (ADL) is engaged into manufacturing and selling Active Pharmaceutical Ingredients (API's), Pharma Intermediates, Specialty Chemicals as well as Formulations. [1] It is exporting its API's and Spec...
Where is Aarti Drugs Ltd (AARTIDRUGS) listed?
Aarti Drugs Ltd trades as AARTIDRUGS on the NSE and under code 524348 on the BSE.
Which sector does Aarti Drugs Ltd belong to?
Aarti Drugs Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Aarti Drugs Ltd?
Aarti Drugs Ltd has a market capitalisation of ₹4,088 Cr as of 28 Oct 2026, which places it in the Small Cap band.
What is the PE ratio of Aarti Drugs Ltd?
Aarti Drugs Ltd trades at a PE ratio of 21.38 as of 28 Oct 2026, on earnings per share of ₹20.95, against a book value of ₹169.7 per share.
What is the 52-week high and low of Aarti Drugs Ltd?
Over the last 52 weeks Aarti Drugs Ltd has traded between ₹318.95 and ₹534 as of 28 Oct 2026.
Does Aarti Drugs Ltd pay dividends?
Aarti Drugs Ltd has a dividend yield of 0.50%.
What is the Return on Equity (ROE) of Aarti Drugs Ltd?
Aarti Drugs Ltd reported a return on equity of 12.58%. Its debt-to-equity ratio is 0.37.

Company Information

Established in the year 1984 and a part of $1000 million Aarti Group of Industries, Aarti Drugs Ltd. (ADL) is engaged into manufacturing and selling Active Pharmaceutical Ingredients (API's), Pharma Intermediates, Specialty Chemicals as well as Formulations. [1] It is exporting its API's and Speciality chemicals to over 100 countries across the globe. [2]

Website aartidrugs.com
CEO Mr. Prakash Moreshwar Patil
Employees 1,284
Listed 2003-09-19
Face Value ₹ 10
Shares Outstanding 9,12,70,000

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/AARTIDRUGS.md for Aarti Drugs Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month